FTL008.16 / Sound Biopharma - LARVOL DELTA

FTL008.16, a 5T4-Conditional 4-1BB bispecific antibody, potently enhances antitumor immunity via tumor-directed t-cell activation. (PubMed, Oncoimmunology) - "Importantly, this 5T4-restricted activation mechanism confines immune stimulation to the tumor microenvironment, thereby circumventing the systemic toxicity associated with conventional 4-1BB agonists. Collectively, these findings establish FTL008.16 as a conditionally active immunotherapeutic agent that successfully achieves both robust antitumor efficacy and a favorable safety profile."

Journal • Oncology • TNFRSF9

Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16 (clinicaltrials.gov) - P1 | N=68 | Recruiting | Sponsor: Sound Biopharmaceuticals Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: May 2027 ➔ Nov 2027 | Trial primary completion date: Jan 2026 ➔ Nov 2026

Enrollment open • Trial completion date • Trial primary completion date • Solid Tumor

Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16 (clinicaltrials.gov) - P1 | N=68 | Not yet recruiting | Sponsor: Sound Biopharmaceuticals Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor